Thursday, October 15, 2020


FDA decision to stop quick review of lab developed tests raises payment concerns for labs

The agency's decision raises questions around reimbursement and liability protections. It could also impact the ability of new lab-developed tests to compete. That's because an emergency use authorization, which the new tests won't have, are often seen as a mark of quality.


No comments: